Introduction : Freedom-to-operate (“FTO”) analysis is a structured legal and commercial assessment of whether a company may research, develop, manufacture, import, market, sell, or otherwise commercialise a pharmaceutical product in a particular jurisdiction without infringing third-party patent rights. It is a risk-management exercise, not a certificate that a product is safe, effective, regulatory-compliant, or free from all intellectual-property disputes.
In the pharmaceutical sector, FTO analysis is particularly important because product development involves substantial investment, long regulatory timelines, complex supply chains, and significant exposure to patent enforcement. A carefully conducted FTO review can inform decisions relating to candidate selection, formulation development, manufacturing strategy, licensing, patent challenges, market entry, and launch timing.
This article explains the purpose of FTO analysis, examines how third-party patent rights may affect compounds, manufacturing processes, formulations, and therapeutic uses, and considers territorial scope, claim interpretation, patent status, design-arounds, and the distinction between patentability and FTO.
What FTO analysis means
FTO analysis seeks to answer a practical commercial question: whether a company can make and commercialise its intended product in a chosen jurisdiction without infringing a third party’s enforceable patent rights. It is different from a patentability assessment, which examines whether the company’s own invention is new, inventive, and otherwise eligible for patent protection.
An FTO analysis does not establish that a product is free from all legal risk. It identifies patents and published patent applications that may present a risk of infringement, assesses the relevance of those rights to the proposed product, and recommends appropriate commercial and legal responses.
In India, the rights conferred by a patent are defined by the Patents Act, 1970. Section 48 provides that, subject to the other provisions of the Act, a patent confers upon the patentee the exclusive right to prevent third parties from commercially exploiting the patented invention in India.
For a product patent, these rights may include preventing third parties, without the patentee’s consent, from making, using, offering for sale, selling, or importing the patented product in India. For a process patent, the rights may include preventing use of the patented process and dealing in India with products obtained directly by that process.
Why FTO analysis matters
Pharmaceutical development is capital-intensive and time-sensitive. A company may spend several years and substantial resources developing a molecule, formulation, manufacturing process, and regulatory dossier before it is in a position to commercialise the product.
FTO analysis helps a company identify patent risks before it becomes commercially committed to a particular product or market. It can prevent avoidable expenditure on a product that may later face infringement proceedings, injunctions, damages claims, import restrictions, or the need for a costly redesign.
For innovator companies, FTO analysis helps identify third-party patents that may block a proposed product or process. For generic and biosimilar companies, it helps identify patents that may need to be licensed, challenged, or designed around before launch.
For in-house counsel, an FTO analysis provides a documented basis for commercial decision-making. It can support investment-committee approvals, board reporting, launch planning, supply-chain decisions, and contractual warranties given to distributors, licensees, or investors.
When FTO analysis should be conducted
FTO analysis should not be treated as a one-time exercise conducted immediately before launch. It is most effective when it is carried out at defined stages of the product lifecycle and updated as the product and the patent landscape evolve.
Early research stage
At the discovery or early-development stage, an FTO review can identify obvious patent barriers before significant resources are committed. At this stage, the review may focus on the active pharmaceutical ingredient (“API”), key intermediates, principal manufacturing routes, and primary therapeutic indications.
The objective at this stage is not to resolve every possible legal issue. Rather, it is to identify high-risk patents and patent families that may require further analysis, licensing discussions, or design-around considerations.
Development stage
As a candidate progresses through development, the FTO review should become more detailed and product-specific. It should cover the final molecule, salt or polymorph, formulation, excipients, manufacturing process, analytical methods, packaging, device components, and intended therapeutic indications.
This is also the stage at which the company should assess whether licensing, patent challenges, or design-arounds are commercially realistic. A patent risk identified late in development may be significantly more expensive and disruptive to address.
Pre-launch stage
Before launch, the company should update the FTO review to reflect newly granted patents, newly published applications, amended claims, oppositions, litigation, licensing arrangements, and any changes to the final commercial product.
The pre-launch review should also consider the exact markets in which the product will be sold, the manufacturing locations, import routes, and the role of distributors, contract manufacturers, and other supply-chain participants.
Scope of an FTO review
A pharmaceutical FTO review should be tailored to the product, the business model, and the intended markets. A review limited only to the active ingredient may fail to identify material risks arising from manufacturing processes, formulations, delivery systems, or therapeutic uses.
Active pharmaceutical ingredient
The FTO review should identify patents and applications claiming the API, its salts, esters, polymorphs, hydrates, solvates, and closely related analogues.
It should also consider patents claiming intermediates, synthetic routes, impurity profiles, crystalline forms, and processes for preparing the API. A product may be free from a patent on the molecule itself but still face risk from a patent covering an essential manufacturing route.
Manufacturing process
Process patents can be particularly important where the company intends to manufacture the product in India or import a product made by a patented process. Under Section 48 of the Patents Act, 1970, a process patentee may prevent use of the patented process and dealing in India with products obtained directly by that process.
The FTO review should therefore assess each commercially relevant manufacturing step, including starting materials, reaction conditions, catalysts, purification methods, crystallisation, milling, sterilisation, and quality-control procedures.
Formulation and excipients
Formulation patents may cover combinations of APIs and excipients, controlled-release systems, stabilisers, coatings, solubilises, and particular dosage forms.
An FTO review should assess the final commercial formulation, not merely the API. It should also consider whether a proposed excipient combination, coating system, or delivery mechanism falls within the scope of a third-party claim.
Therapeutic use and indications
Patents may claim a compound for use in the manufacture of a medicament, a method of treatment, or a specific therapeutic indication. The scope of protection depends heavily on the wording of the claim and the applicable law.
In India, Section 3(i) excludes certain methods of treatment from patentability, but product claims may still refer to therapeutic use in permitted forms. The FTO review should assess whether the company’s intended indication falls within the scope of a third-party claim.
Delivery systems and devices
For inhalers, injectors, patches, implants, and other combination products, the FTO review should extend beyond the drug substance. It should include device geometry, mechanisms, sensors, software features, user interfaces, and methods of administration where these are claimed.
A drug may be clear of patent risk, but the delivery device may not be. Conversely, a device may be clear while the formulation or therapeutic use remains blocked.
Territorial scope of FTO analysis
FTO analysis is territorial because patent rights are territorial. A patent granted in India gives rights in India, not worldwide.
The company should map the analysis to:
- The country where the product will be manufactured.
- The country where the product will be sold.
- The countries through which the product will be imported or transited, where relevant.
- The countries where clinical trials, regulatory filings, or commercial supply will occur.
In India, infringement actions are subject to the jurisdictional rules under Section 104 of the Patents Act, 1970. A suit for infringement may be instituted in a court not inferior to a district court having jurisdiction to try the suit.
Where a defendant files a counterclaim for revocation of the patent, the infringement suit and the counterclaim are transferred to the High Court for decision.
This jurisdictional framework matters because an FTO risk is not merely theoretical. It should be assessed against the courts, remedies, and enforcement mechanisms available in the relevant market.
Claim interpretation in FTO analysis
The central question in FTO analysis is not whether a patent exists, but whether the company’s product or process falls within the claims. Patent claims define the boundaries of legal protection and form the “protective fence” around the invention.
The Indian Patent Office Manual states that claims define the contours of rights, if and when a patent is granted for an invention. It further states that a claim is a statement of technical facts expressed in legal terms defining the scope of the invention sought to be protected.
The Manual also states that no exclusivity is obtained for any matter described in the complete specification unless it is claimed. What is not claimed, including after amendment, is open to public use even if described in the specification.
This principle is important for FTO analysis. A patent specification may describe many possible embodiments, but only the claims define the legal monopoly.
Independent and dependent claims
An FTO review should begin with the independent claims, because these define the broadest protected subject matter. Dependent claims may become relevant if the independent claim is narrowed, amended, or found invalid.
The review should not stop at the first independent claim. It should identify all independent claims in the patent family and assess whether the company’s product falls within any of them.
Claim terms and technical meaning
Terms such as “substantially,” “about,” “effective amount,” “pharmaceutically acceptable,” and “consisting essentially of” can materially affect infringement analysis. Their meaning may depend on the specification, prosecution history, expert evidence, and judicial interpretation.
The FTO analysis should identify claim terms that are unclear, potentially broad, or likely to be contested. It should also assess whether the company’s product falls within the literal claim scope or may be argued to fall within an equivalent scope.
Prosecution history
The prosecution history can be highly relevant. Amendments, arguments, and disclaimers made during examination may narrow the scope of the claims or limit the patentee’s ability to assert them broadly.
The FTO review should therefore examine office actions, responses, amended claims, and any statements made by the applicant. This is particularly important where a patent has been amended to overcome an objection.
Patent status and legal risk
An FTO analysis should distinguish between patents that are granted, pending, expired, abandoned, revoked, or subject to opposition or litigation. The legal risk associated with each category is different.
Granted patents
A granted patent presents the most direct FTO risk because it confers enforceable exclusive rights. The review should assess claim scope, remaining term, ownership, licensing status, and any known challenges.
It should also consider whether the patent has been commercially worked in India, as this may be relevant to certain statutory remedies and compulsory-licensing issues.
Pending applications
A pending application does not yet confer enforceable patent rights, but it may do so in future. The FTO review should monitor pending applications, especially those with claims that could cover the company’s product.
The company should also consider whether it can file observations, oppositions, or other procedural responses, depending on the applicable rules and timing.
Expired or abandoned patents
An expired patent generally does not create FTO risk, but the review should confirm the expiry date and whether any patent-term adjustment, extension, or restoration applies in the relevant jurisdiction.
An abandoned application may also be relevant if it has been revived, if a related application remains pending, or if the disclosure affects obviousness arguments in a later patent challenge.
Revoked or invalidated patents
A revoked patent may no longer create FTO risk, but the company should confirm the finality of the decision and whether an appeal is pending.
The review should also assess whether related patents or applications in the same family remain in force. A revocation in one jurisdiction does not automatically invalidate corresponding rights elsewhere.
Compounds, processes, formulations and uses
A pharmaceutical FTO review should be structured around the different layers of protection that may exist around a product.
Compound patents
Compound patents may cover the API itself, its salts, derivatives, or closely related structures. These are often the most fundamental barriers because they may cover the active molecule regardless of formulation or manufacturing route.
The review should assess whether the company’s molecule falls within the claimed Markush structure, chemical genus, or specific compound. It should also consider whether the company’s molecule is covered by a claim to a class of compounds.
Process patents
Process patents may cover the synthesis of the API, intermediates, purification, crystallisation, or final dosage-form manufacture.
The review should map the company’s actual manufacturing process against the claimed process. It should identify steps that may be avoided, substituted, or redesigned.
Formulation patents
Formulation patents may cover the combination of API and excipients, controlled-release profiles, stabilisers, coatings, and dosage forms.
The review should assess the final commercial formulation, including any changes made during development. It should also consider whether the company’s formulation falls within a claim to a class of formulations.
Therapeutic-use patents
Therapeutic-use patents may cover a new indication, patient population, dosing regimen, or combination therapy.
The review should assess whether the company’s intended use falls within the claimed indication. It should also consider whether the company’s labelling, promotional materials, or clinical-trial design could create infringement exposure.
Design-arounds and risk mitigation
A design-around is a deliberate change to the product, process, or formulation to avoid a third-party patent claim. It is not merely a cosmetic change; it must genuinely fall outside the claim scope.
Product design-arounds
A product design-around may involve changing the salt form, polymorph, excipient combination, dosage form, or delivery system. The change must be assessed against the actual claim language, not against a general description in the specification.
For example, if a patent claims a specific crystalline form, the company may consider a different form, but only if that form is not covered by another claim or patent.
Process design-arounds
A process design-around may involve changing a reagent, catalyst, reaction condition, purification method, or crystallisation route. The change must be assessed against the claimed process steps.
The company should also consider whether the changed process produces a product obtained directly by a patented process, which may still create risk under Indian law.
Licensing and acquisition
Where a design-around is not commercially feasible, the company may consider licensing the relevant patent or acquiring the patent or the underlying business.
Licensing should address scope, territory, field of use, royalties, sublicensing, improvements, and termination. It should also address whether the licence covers future patent families or only existing rights.
Patent challenges
Where the patent is weak, the company may consider challenging validity through opposition, revocation, or litigation, depending on the jurisdiction and timing.
In India, a defendant in an infringement action may file a counterclaim for revocation, which is transferred to the High Court along with the infringement suit.
Commercial redesign
In some cases, the company may decide to change the product concept, indication, or market. This may be preferable where the patent risk is high and the commercial value of the affected market is limited.
Patentability versus FTO
Patentability and FTO are often confused, but they answer different questions.
| Issue | Patentability | Freedom to operate |
|---|---|---|
| Core question | Can the company obtain a patent for its invention? | Can the company commercialise without infringing third-party rights? |
| Focus | The company’s own invention | Third-party patents and applications |
| Key test | Novelty, inventive step, industrial applicability, and statutory exclusions | Claim infringement and enforceability |
| Relevant documents | Prior art, specifications, claims, examination reports | Third-party claims, prosecution history, litigation, licences |
| Practical outcome | Filing and prosecution strategy | Licensing, design-around, challenge, delay, or launch decision |
A company may obtain a patent for its own invention and still be unable to commercialise it because a third party holds an earlier, broader patent. Conversely, a company may be unable to obtain a patent but may still be free to commercialise because no third-party claim covers its product.
This distinction is especially important in pharmaceutical development. A new formulation may be patentable, but it may still infringe an earlier patent on the API, a manufacturing process, or a therapeutic use.
Practical FTO workflow
A robust FTO workflow should be documented, repeatable, and updated as the product evolves.
Define the product
The first step is to define the exact commercial product, including the API, salt or polymorph, formulation, dosage form, manufacturing route, packaging, device, and intended indication.
The review should also identify the markets in which the product will be sold and the manufacturing locations.
Search and screen
The next step is to search patents, published applications, and relevant non-patent literature. The search should cover the API, intermediates, process steps, formulation, delivery system, and therapeutic use.
The search should be updated regularly, because new applications and grants can change the risk profile.
Claim mapping
The company should map each relevant claim against the product or process. This should be done at the level of individual claim elements, not merely at the level of the patent title or abstract.
The mapping should identify claims that are clearly not infringed, claims that are potentially infringed, and claims that require further legal or technical analysis.
Legal assessment
For potentially relevant patents, the company should assess claim construction, prosecution history, validity risk, ownership, licensing status, and litigation history.
The assessment should also consider whether the patent is likely to be enforced, whether the patentee is active in the market, and whether the company has a realistic design-around.
Risk reporting
The final output should be a clear, decision-oriented report. It should identify the product, jurisdiction, relevant patents, risk level, recommended action, and assumptions.
The report should distinguish between legal conclusions and commercial judgements. It should also identify any information gaps or assumptions that could change the analysis.
Common mistakes to avoid
Companies often make avoidable mistakes in FTO analysis. These can be reduced through disciplined process and early legal involvement.
- Treating FTO as a one-time exercise rather than a lifecycle process.
- Limiting the review to the API and ignoring process, formulation, or device patents.
- Relying on patent abstracts instead of analysing claims.
- Ignoring pending applications and patent families.
- Failing to update the review before launch.
- Assuming that a patentability opinion establishes FTO.
- Assuming that a design-around is safe without claim-level analysis.
- Failing to document assumptions, search dates, and legal conclusions.
Conclusion
FTO analysis is a practical risk-management tool that helps pharmaceutical companies make informed decisions before committing to a product, process, or market. It should be tailored to the exact commercial product, updated through development, and grounded in claim-level legal analysis.
For Indian companies, the analysis should account for the territorial nature of patent rights, the scope of rights under Section 48 of the Patents Act, 1970, and the jurisdictional framework under Section 104.
Ultimately, FTO analysis does not eliminate risk. It makes risk visible, measurable, and manageable, allowing companies to choose between licensing, redesign, challenge, delay, or commercialisation with greater confidence.
The issues surrounding biologics, biosimilar competition, patent exclusivity and the U.S. patent dance form part of the broader developments in pharmaceutical and biotechnology intellectual property. These themes will also be addressed at Pharma Symposium 2026, organised by Khurana & Khurana and IIPRD, in association with international organising partners Carlson Caspers (USA), Bonabry (Germany and France), and Tee & Howe (China). The symposium will take place in Hyderabad on 7–8 December 2026 at Park Hyatt Hyderabad, followed by Mumbai on 9–10 December 2026 at Hilton Mumbai. Its programme includes discussions on U.S. pharmaceutical patent litigation, biosimilar case law, regulatory exclusivity, patent lifecycle management and pharmaceutical patent developments across the United States, Europe, China and India.
Author : Vipasha Srivastava, In case of any queries please contact/write back to us via email to [email protected] or at IIPRD
Endnotes
- Patents Act, 1970, Section 48, Intellectual Property India, available at: https://ipindia.gov.in/acts/patent-act-1970/section-48.ipindia.gov
- Patents Act, 1970, Section 104, Intellectual Property India, available at: https://ipindia.gov.in/acts/patent-act-1970/section-104.ipindia.gov+1
- Patents Act, 1970, Section 105, Intellectual Property India, available at: https://ipindia.gov.in/acts/patent-act-1970/section-105.ipindia.gov
- Patents Act, 1970, Section 106, Intellectual Property India, available at: https://ipindia.gov.in/acts/patent-act-1970/section-106.ipindia.gov
- Manual of Patent Office Practice and Procedure, Intellectual Property India, available at: https://www.ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_28_1_manual-of-patent-office-practice_and-procedure.pdf.ipindia.gov+1
- Guidelines for Search and Examination of Patent Applications, Intellectual Property India, available at: https://ipindia.gov.in/storage/uploads/docs-operator/e23412b4-6beb-4a55-a7ae-276aaed28eaf.pdf.ipindia.gov
- Pharmaceuticals Patent Guidelines, CGPDTM, Intellectual Property India, available at: https://www.ipindia.gov.in/storage/uploads/docs-operator/9f0c33bd-3aca-42f6-aff8-3acc28a0d5bf.pdf.